New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

Stopped early

Conditions studied: Retinitis Pigmentosa

In brief

This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.

Key facts

Study ID

NCT01860092

Run by

Second Sight Medical Products

People needed

53

Starts

2014-01-01

Expected to finish

2020-03-01

Last updated by the study team

2021-12-23

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are adults, age 25 year or older;
• Have severe to profound retinitis pigmentosa;
• Bare light or no light perception in both eyes; if the patient has no residual light perception, then evidence of intact inner layer retina function must be confirmed;
• Have previous history of useful form vision.
• Aphakic or pseudophakic. (If the patient is phakic prior to implant, the natural lens will be removed during the implant procedure.)
• Patients who are willing and able to receive the recommended post-implant clinical follow-up, device fitting, and visual rehabilitation;
• Have consented to the implantation of an Argus II Retinal Prosthesis and subsequently consent to participate in this study;
• At the time of the Baseline Visit, do not suffer from non-ophthalmic serious adverse events (e.g. myocardial infarction, etc.) and

You may not qualify if…

• Ocular diseases or conditions that could prevent Argus II System from working (e.g. optic nerve disease, central retinal artery or vein occlusion, history of retinal detachment, trauma, severe strabismus);
• Ocular structures or conditions that could prevent the successful implantation of the Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva, axial length <20.5 mm or >26 mm, corneal ulcers, etc.);
• Ocular diseases or conditions (other than cataracts) that prevent adequate visualization of the inner structures of the eye (e.g. corneal opacity, etc.);
• Inability to tolerate general anesthesia or the recommended antibiotic and steroid regimen associated with the implantation surgery;
• Metallic or active implantable device(s) (e.g. cochlear implant) in the head;
• Pre-disposition to eye rubbing;
• Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
• cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease,
• psychiatric disease including diagnosed forms of depression;
• does not speak a principal language associated with the region, and
• deafness;
• Pregnant or wish to become pregnant during the course of the study;
• Participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study;
• Conditions likely to limit life to less than 1 year from the time of inclusion.

Where it is running

• University of Southern California — Los Angeles, California, United States
• University of Colorado, Denver — Denver, Colorado, United States
• U. of Miami, Bascom Palmer Eye Institute — Miami, Florida, United States
• University of Miami Bascom Palmer Eye Institute — Miami, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Retina Consultants of Hawaii — ‘Aiea, Hawaii, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• Johns Hopkins, Lions Vision Center — Baltimore, Maryland, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• University of Michigan, Kellogg Eye Center — Ann Arbor, Michigan, United States
• University of Minnesota Department of Ophthalmology — Minneapolis, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Stony Brook University — East Setauket, New York, United States
• Duke University Eye Center — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Wills Eye Hospital / Mid Atlantic Retina — Philadelphia, Pennsylvania, United States
• Retina Foundation of the Southwest — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.